Bone disease in chronic renal failure and its modern therapy;Kostní choroba u chronického selhání ledvin a její moderní terapie

Vnitrni Lekarstvi

Volumn 57, Issue 7-8, 2011, Pages 620-625

  Dusilová Sulková, Sylvie ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Bone disease; Chronic renal failure; Secondary hyperparathyreosis

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CALCIUM RECEPTOR; PHOSPHATE BINDING AGENT; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; BONE TISSUE; CALCINOSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; MODULATION; PATHOGENESIS; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; RENAL OSTEODYSTROPHY;

EID: 80051965147     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dusilová Sulková S a kol. Renální osteopatie. Praha: Maxdorf Jessenius 2007.
2. Dusilová Sulková S. Kostní a minerá lová porucha při chronickém onemocnění ledvin - přehled problematiky. Osteol Bull 2008; 13: 144-151.
3. Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-835.
4. Martin KJ, Olgard K, Coburn JW et al. Bone Turnover Work Group. Diagnosis, assessment and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43: 558-565. (Pubitemid 38298216)
5. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740. (Pubitemid 37098542)
6. Moe SM, Drüeke TB, Cunningham J et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation and classification of renal osteodysstrophy. A position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
7. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression and therapeutic options. Clin J Am Soc Nephrol 2011; 6: 913-921.
8. Martin KJ, González EA. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: What is normal, when to start and how to treat. Clin J Am Soc Nephrol 2011; 6: 440-446.
9. Rodriguez M, Canalejo A, Garfia B et al. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int 2002; 61: S155-S160.
10. Dusilová Sulková S, Opatrná S, Ryšavá R et al. KDIGO doporučení pro diagnostiku a léčbu CKD-MBD: komentovaný návod pro klinickou praxi. Aktuality v nefrologii 2010; 16: 113-126.
11. Kidney Disease: Improving Global Outcome (KDIGO) CKD-MBD working group. KDIGO clinical practice guideline for the diagnosis, evaluation, preventive and treatment of chronic kidney disease mineral bone disorder (CKD-MBD). Kidney Int 2009; 76 (Suppl 113): S1-S130.
12. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 Suppl 3): S1-S201.
13. Komaba H, Nakanishi S, Fujimori A et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 2305-2314.
14. Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589.
15. Souberbielle JC, Cavaleire E, Jean G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for clinical laboratory? Clin Chem Lab Med 2010; 48: 769-774.
16. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downeard spiral in kidney disease. Kidney Int 2011; 79: 715-729.
17. Szeto CC, Li PKT. The use of vitamin D analogues in chronic kidney diseases: possible mechanisms betone bone and mineral metabolism. NDT Plus 2009; doi.10.1093/ndtplus/sfp034.
18. Emmet M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int 2004; 66 (Suppl 90): S25-S32.
19. McIntyre CW. New developments in the management of hyperphosphatemia in chronic kidney disease. Semin Dial 2007; 20: 337-341.
20. Gordon PL, Frassetto LA. Management of osteoporosis in CKD stages 3 to 5. Am J Kidney Dis 2010; 55: 941-956.
21. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009; 4: 221-233.
22. Tominaga Y, Matsuoka S, Uno N et al. Parathyreoidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 2008; 12 (Suppl 1): S21-S26.
23. Rodriguez M, Nemeth E, Martin D. The calcium-sension receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: 253-264.
24. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Clin Res 2004; 95: 560-567. (Pubitemid 39274370)
25. Dusilová Sulková S, Válek M. Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis. Nutrition 2010; 26: 910-914.
26. Floege J, Kim J, Ireland E et al. ARO Investigators. Serum iPTH, calcium, phosphate, and the risk of mortality in a European hemodialysis population. Nephrol Dial Transplant 2010. [Epub ahead of print].
27. Kalantar-Zadeh K, Shah A, Duoung U et al. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int 2010; 78 (Suppl 117): S10-S21.